Hepatology:清华大学陈立功课题组报道氨基酸转运蛋白在肝癌发生过程中的重要调节作用

2017-04-10 佚名 生物帮

近日,国际肝病学领域著名学术期刊《Hepatology》在线发表了清华大学药学院陈立功课题组及其合作者题为“A functional mTORC1 signaling is indispensable for c-Myc driven hepatocarcinogenesis”的文章,阐述了氨基酸转运蛋白在肝癌发生过程受原癌基因c-Myc调控进而激活mTORC1信号通路诱导肝癌形成。清华大学生命科

近日,国际肝病学领域著名学术期刊《Hepatology》在线发表了清华大学药学院陈立功课题组及其合作者题为“A functional mTORC1 signaling is indispensable for c-Myc driven hepatocarcinogenesis”的文章,阐述了氨基酸转运蛋白在肝癌发生过程受原癌基因c-Myc调控进而激活mTORC1信号通路诱导肝癌形成。清华大学生命科学院博士生葛梦梦和UCSF刘玭为论文共同第一作者,药学院研究生程丽丽、孙焜和本科生黄越冬为本论文的合作作者,清华大学药学院陈立功研究员以及UCSF Xin Chen教授为论文通讯作者。

Hepatocellular carcinoma (HCC)肝细胞癌是最常见的恶性肿瘤之一。原癌基因c-Myc是引发肝癌主要基因之一,促进细胞恶变,最后导致肿瘤的发生在小鼠肝脏中过表达c-Myc能引起肿瘤的形成,但是c-Myc致癌的分子机制仍然知之甚少。我们发现mTORC1信号通路的激活是c-Myc诱导肝癌形成的必要条件, mTOR 下游效应器真核细胞翻译启始因子4E 结合蛋白1 4EBP1 / eIF4E和核糖体蛋白S6 激酶1 p70S6K 共同调节细胞增殖。氨基酸作为细胞生长和增殖的必要条件,对mTORC1正常发挥功能起着至关作用,转录组学数据分析表明c-Myc能够上调多种氨基酸转运蛋白的表达,如SLC1A5和SLC7A6,它们属于膜转运蛋白的溶质载体(SLC)家族,这些转运蛋白在各种生理和病理过程中具有关键的作用。代谢组学分析表明c-Myc直接上调SLC1A5和SLC7A6,导致肝癌细胞对氨基酸的吸收增加进而激活mTORC1信号通路。在人类HCC标本中,c-Myc的水平和SLC1A5 / SLC7A6表达之间有很大的相关性。总之,这些数据表明在肝癌的治疗过程中,除了靶向mTOR信号通路以外,SLC氨基酸转运蛋白家族也渐渐成为有效的药物的靶标,成为治疗HCC有效选择。

原始出处:

Pin Liu,Mengmeng Ge,Junjie Hu,et al.A functional mTORC1 signaling is indispensable for c-Myc driven hepatocarcinoGENEsis.Hepatology. 2017 Mar 30

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1860829, encodeId=6f58186082908, content=<a href='/topic/show?id=5e746403ed5' target=_blank style='color:#2F92EE;'>#氨基酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64037, encryptionId=5e746403ed5, topicName=氨基酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Sep 02 01:35:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696272, encodeId=3eed16962e25d, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Sat Jan 13 21:35:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186807, encodeId=d11a18680eac, content=肿瘤代谢还是有很多值得研究开发的点~, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Wed Apr 12 07:50:33 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426715, encodeId=e7861426e1545, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Wed Apr 12 04:35:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500101, encodeId=29dc150010100, content=<a href='/topic/show?id=9e6866216d7' target=_blank style='color:#2F92EE;'>#清华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66216, encryptionId=9e6866216d7, topicName=清华)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29422809, createdName=医生2397, createdTime=Wed Apr 12 04:35:00 CST 2017, time=2017-04-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1860829, encodeId=6f58186082908, content=<a href='/topic/show?id=5e746403ed5' target=_blank style='color:#2F92EE;'>#氨基酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64037, encryptionId=5e746403ed5, topicName=氨基酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Sep 02 01:35:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696272, encodeId=3eed16962e25d, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Sat Jan 13 21:35:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186807, encodeId=d11a18680eac, content=肿瘤代谢还是有很多值得研究开发的点~, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Wed Apr 12 07:50:33 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426715, encodeId=e7861426e1545, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Wed Apr 12 04:35:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500101, encodeId=29dc150010100, content=<a href='/topic/show?id=9e6866216d7' target=_blank style='color:#2F92EE;'>#清华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66216, encryptionId=9e6866216d7, topicName=清华)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29422809, createdName=医生2397, createdTime=Wed Apr 12 04:35:00 CST 2017, time=2017-04-12, status=1, ipAttribution=)]
    2018-01-13 yzh409
  3. [GetPortalCommentsPageByObjectIdResponse(id=1860829, encodeId=6f58186082908, content=<a href='/topic/show?id=5e746403ed5' target=_blank style='color:#2F92EE;'>#氨基酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64037, encryptionId=5e746403ed5, topicName=氨基酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Sep 02 01:35:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696272, encodeId=3eed16962e25d, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Sat Jan 13 21:35:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186807, encodeId=d11a18680eac, content=肿瘤代谢还是有很多值得研究开发的点~, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Wed Apr 12 07:50:33 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426715, encodeId=e7861426e1545, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Wed Apr 12 04:35:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500101, encodeId=29dc150010100, content=<a href='/topic/show?id=9e6866216d7' target=_blank style='color:#2F92EE;'>#清华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66216, encryptionId=9e6866216d7, topicName=清华)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29422809, createdName=医生2397, createdTime=Wed Apr 12 04:35:00 CST 2017, time=2017-04-12, status=1, ipAttribution=)]
    2017-04-12 Jianghuiqin

    肿瘤代谢还是有很多值得研究开发的点~

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1860829, encodeId=6f58186082908, content=<a href='/topic/show?id=5e746403ed5' target=_blank style='color:#2F92EE;'>#氨基酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64037, encryptionId=5e746403ed5, topicName=氨基酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Sep 02 01:35:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696272, encodeId=3eed16962e25d, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Sat Jan 13 21:35:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186807, encodeId=d11a18680eac, content=肿瘤代谢还是有很多值得研究开发的点~, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Wed Apr 12 07:50:33 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426715, encodeId=e7861426e1545, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Wed Apr 12 04:35:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500101, encodeId=29dc150010100, content=<a href='/topic/show?id=9e6866216d7' target=_blank style='color:#2F92EE;'>#清华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66216, encryptionId=9e6866216d7, topicName=清华)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29422809, createdName=医生2397, createdTime=Wed Apr 12 04:35:00 CST 2017, time=2017-04-12, status=1, ipAttribution=)]
    2017-04-12 gwc384
  5. [GetPortalCommentsPageByObjectIdResponse(id=1860829, encodeId=6f58186082908, content=<a href='/topic/show?id=5e746403ed5' target=_blank style='color:#2F92EE;'>#氨基酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64037, encryptionId=5e746403ed5, topicName=氨基酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Sep 02 01:35:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696272, encodeId=3eed16962e25d, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Sat Jan 13 21:35:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186807, encodeId=d11a18680eac, content=肿瘤代谢还是有很多值得研究开发的点~, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Wed Apr 12 07:50:33 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426715, encodeId=e7861426e1545, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Wed Apr 12 04:35:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500101, encodeId=29dc150010100, content=<a href='/topic/show?id=9e6866216d7' target=_blank style='color:#2F92EE;'>#清华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66216, encryptionId=9e6866216d7, topicName=清华)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29422809, createdName=医生2397, createdTime=Wed Apr 12 04:35:00 CST 2017, time=2017-04-12, status=1, ipAttribution=)]
    2017-04-12 医生2397

相关资讯

多项靶向药物折戟沉沙|如何打破肝癌治疗的魔咒?

众所周知,我国是世界范围内的肝癌大国。每年全球新发的肝癌患者中,中国约占57%。而全球因肝癌而死亡患者中,有45%~50%来自中国。中国的肝癌发病率和死亡率分列我国所有恶性肿瘤的第5位和第2位。肝癌是一类具有典型“地域特色”的恶性肿瘤。在欧美国家,肝癌主要是由丙型肝炎病毒感染和代谢性肝病等因素引起。在我国,肝癌的主要病因则是乙型肝炎病毒感染,酒精和黄曲霉等生物因素也是常见的致病原因。此外,我国

HEPATOLOGY:上海药物所揭示 pIgR/p-Yes 亚群分型是肝癌患者生存的预后标志物

高表达 pIgR 体内外显著促进肝癌细胞恶性增殖和肿瘤生长。分子机制研究表明,介导 pIgR 免疫转运的关键激酶 Yes 参与调控了 pIgR 介导的肿瘤生长效应;深入机制研究发现,pIgR 通过募集活化 Yes,启动了基于 ITAM 基序的经典免疫受体相关通路介导肿瘤生长。

“院士+”公益项目落地——“恒瑞介入关爱基金”助力我国肝癌介入事业再攀高峰

2016年,由12位中国科学院、中国工程院院士共同捐款发起的中国红十字基金会“院士博爱基金”成立。这是中国首个由两院院士发起成立的专项公益基金。2017年3月24日,“院士博爱基金”成立一年之际,在“院士+”公益效应影响下设立的首个专项基金——“恒瑞介入关爱基金”在上海正式启动,该项基金由中国红十字基金会携手江苏恒瑞医药股份有限公司成立。

科学家找到肝癌的“罪魁祸首”,80%&#160都是由它引起

在世界上的很多国家,包括东南亚和撒哈拉以南地区,80% 的肝癌病例是由于受到真菌黄曲霉毒素的影响。这种真菌通常可以在玉米,花生和其他作物中找到,也是这些地区的主要食品。今日,来自麻省理工大学的研究人员开发出一种方法,通过干细胞的 DNA 排序,观察这些细胞是否受到黄曲霉毒素的影响。这一突变侧写可以帮助研究人员识别人们是否有患肝癌的风险,可能在肿瘤形成的几年前就可以提前预测出来。来自麻省理工

Gastroenterology:驱虫药氯硝柳胺或可治肝癌

肝细胞癌(HCC)是一种与潜在的肝脏疾病和肝硬化相关的癌症,它在进展非常迅速的情况下往往只会出现症状,是世界上癌症死亡的第二大原因,但目前还没有有效的治疗方法。

常见突变有助于早期肝癌检测

在世界上的很多地方,包括非洲西部以及撒哈拉地区,感染黄曲霉(一种常见真菌)导致80%的肝癌发生。而这种真菌常见于玉米、花生以及其它常见的作物中。如今,来自MIT的研究者们开发出了一种通过对肝脏细胞DNA测序检测这些细胞是否感染黄曲霉菌的方法。检测到如果有特定的突变出现,那么将很有可能面临较大的